Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy

DNA is the well-known molecular target of current platinum-based anticancer drugs; consequently, their clinical use is severely restricted by their systemic toxicities and drug resistance originating from non-selective DNA damage. Various strategies have been developed to circumvent the shortcomings...

詳細記述

保存先:
書誌詳細
出版年:Biochem Pharmacol
主要な著者: Zhao, Chong, Chen, Xin, Zang, Dan, Lan, Xiaoying, Liao, Siyan, Yang, Changshan, Zhang, Peiquan, Wu, Jinjie, Li, Xiaofen, Liu, Ningning, Liao, Yuning, Huang, Hongbiao, Shi, Xianping, Jiang, Lili, Liu, Xiuhua, He, Zhimin, Wang, Xuejun, Liu, Jinbao
フォーマット: Artigo
言語:Inglês
出版事項: 2016
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5287571/
https://ncbi.nlm.nih.gov/pubmed/27381943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2016.06.019
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料